Cutia Therapeutics reported that its authorized share capital remains at USD 50,000, represented by 2,500,000,000 ordinary shares with a par value of USD 0.00002 each. The total issued share count at the end of January 2026 was 364,730,877 shares, comprising 363,368,277 non-treasury shares and 1,362,600 treasury shares. The company confirmed compliance with the applicable public float requirement of 25%.

Regarding share options under the Pre-IPO Equity Incentive Plan’s Share Option Program, 2,786,176 options were exercised during January 2026. These exercises were satisfied by existing shares held by trustees, resulting in total funds raised of USD 709,415.47. At month-end, there were 19,184,484 outstanding share options, and 7,232,620 shares remained available under the Pre-IPO Equity Incentive Plan. No new shares were issued, and no treasury shares were transferred during the month.